Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Primary Biliary Cholangitis
NCT03742973Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2019
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of baricitinib in primary biliary cholangitis (PBC), sponsored by Eli Lilly and Company. Started Mar 2019; status: terminated.
02
Drugs
baricitinib
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03742973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742973.